IMUX

Immunic (IMUX)

About Immunic (IMUX)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

Details

Daily high

$12.09

Daily low

$11.25

Price at open

$11.64

52 Week High

$15.10

52 Week Low

$5.06

Market cap

1.1B

Dividend yield

0.00%

Volume

221,518

Avg. volume

289,051

P/E ratio

-11.79

Immunic News